BioSpace News Archive

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today that OrbiMed Advisors LLC (“OrbiMed”), a significant shareholder of the Company, intends to vote in favor of the proposed merger with Menlo Therapeutics at the Company’s upcoming extraordinary general meeting of shareholders

Tetra Bio Pharma Inc. announced that Health Canada has granted two Drug Identification Numbers for the first over-the-counter products to be marketed under its TERPACAN™ banner..

111, Inc. (NASDAQ: YI) (“111" or the “Company”), a leading integrated online and offline healthcare platform, announced the release of the fifth episode in its 111 Insight series.

HEXO Corp (“HEXO” or the “Company”) (TSX: HEXO; NYSE: HEXO) today announced it has entered into a definitive agreement with institutional investors for the purchase and sale of 11,976,048 common shares at an offering price of US$1.67 per share for gross proceeds of US$20.0 million before deducting fees and other estimated offering expenses, pursuant to a registered direct offering (the “Offering”)

Laura van ‘t Veer, Ph.D., co-founder of Agendia Inc. and developer of MammaPrint, the 70-gene risk of recurrence assay for breast cancer patients, will be recognized by Precision Medicine World Conference with the PMWC Luminary Award on January 21, 2020.

The Society of Academic Urologists and the American Urological Association announced the results of the 2020 Urology Residency Match, the system through which U.S. medical students, and other applicants from around the world wishing to specialize in urology, learn where they will complete their residency.

Technavio has announced its latest market research report titled global ureteroscopy devices market 2019-2023.

AMPEL BioSolutions’ Co-Founder and COO/CSO Dr. Amrie Grammer today at the Biotech Showcase at JP Morgan Healthcare announces the kickoff of a Series A $12.5M raise to commercialize LuGENETM, a gene-based diagnostic.

NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2019 fourth quarter and full year financial results before the opening of the market on Thursday, January 23, 2020.

Genomic medicine’s groundbreaking treatments, and its future promise, will be the focus of a full-day symposium at the Hackensack Meridian Health Center for Discovery and Innovation (CDI) on Wednesday, February 19.